Hvilken er prisen på Gracell Biotechnologies Inc. (GRCL)

Prisen på Gracell Biotechnologies Inc. (GRCL) er $10.25

Hva er markedsverdien på Gracell Biotechnologies Inc. (GRCL)

Markedsverdien på Gracell Biotechnologies Inc. (GRCL) er $137.83M

Gracell Biotechnologies Inc. (GRCL) Aksjesplitter

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.